Form 4 for XAIR Beyond Air, Inc.
Accepted 2026-07-31 18:55:38 ET · period of report 2026-07-29 · accession 0001493152-26-035702 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-31 18:55 | 2026-07-29 | XAIR | Goodman Robert Scott | CEO, Dir | P - Purchase | $5.76 | +34.7K | 34.8K | +34,722% | +$200.0K |
| DM | 2026-07-31 18:55 | 2026-07-29 | XAIR | Goodman Robert Scott | CEO, Dir | P - Purchase | — | +69.4K | 34.7K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-29 | P | A | 34,722 | $5.76 | 34,822 | D | — | — | |
| 2 | Derivative | Series A Warrants | 2026-07-29 | P | A | 34,722 | — | 34,722 | D | $5.51 · — to — | 34,722 Common Stock | (F3) Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76. (F1) Exercisable immediately upon issuance (F2) Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II |
| 3 | Derivative | Series B Warrants | 2026-07-29 | P | A | 34,722 | — | 34,722 | D | $5.51 · — to — | 34,722 Common Stock | (F3) Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76. (F1) Exercisable immediately upon issuance (F4) 5 years following date of issuance |